AnnaMVargheseMD

Physician

Overview of Dr. Varghese

Dr. Anna Varghese is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Memorial Hospital for Cancer and allied Diseases. She received her medical degree from Case Western Reserve University School of Medicine and has been in practice 11 years. She is one of 503 doctors at Memorial Sloan Kettering Cancer Center and one of 87 doctors at Memorial Hospital for Cancer and allied Diseases who specialize in Oncology. She has more than 60 publications and over 500 citings.

Office
160 East 53rd Street
New York, NY 10022
Book by Phone+1(231) 508-9712

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2010 - 2013
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2006 - 2009
Case Western Reserve University School of MedicineClass of 2006

Certifications & Licensure

FL State Medical License 2021 - Present
CT State Medical License 2023 - 2025
NJ State Medical License 2009 - 2025
NY State Medical License 2010 - 2025
NH State Medical License 2024 - 2024
NC State Medical License 2020 - 2022
MA State Medical License 2009 - 2011
American Board of Internal Medicine Medical Oncology

Clinical Trials

A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer Start of enrollment: 2016 Jun 15
Completed
Phase 1
Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer Start of enrollment: 2020 Oct 13
RECRUITING
PHASE3
A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer Start of enrollment: 2018 Mar 07
Recruiting
Phase 2
Roles: Principal Investigator, Contact

Publications & Presentations

PubMed

1 citations
RNA neoantigen vaccines prime long-lived CD8T cells in pancreatic cancer.
Zachary Sethna, Pablo Guasp, Charlotte Reiche, Martina Milighetti, Nicholas Ceglia
Nature. 2025-03-01
Adjuvant modified FOLFIRINOX for resected pancreatic adenocarcinoma: clinical insights and genomic features from a large contemporary cohort.
Fergus Keane, Catherine O'Connor, Drew Moss, Joanne F Chou, Maria A Perry
Journal of the National Cancer Institute. 2025-03-01
2 citations
Long-term outcomes in patients with advanced intrahepatic cholangiocarcinoma treated with hepatic arterial infusion chemotherapy.
Darren Cowzer, Kevin Soares, Henry Walch, Mithat Gönen, Taryn M Boucher
Journal of the National Cancer Institute. 2025-02-01

Lectures

Young-onset pancreas cancer (PC) in patients less than or equal to 50 years old at Memorial Sloan Kettering (MSK): Descriptors, genomics, and outcomes.
ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
Non-invasive detection of acquired resistance to FGFR inhibition in patients with cholangiocarcinoma harboring FGFR2 alterations.
2019 ASCO Annual Meeting - 6/1/2019
A phase I expansion study of trifluridine and tipiracil (FTD/TPI) in combination with irinotecan (IRI) and bevacizumab (BEV) in patients with metastatic colorectal can...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018